CN109311893A - 含有取代环戊基的吡咯并嘧啶化合物 - Google Patents

含有取代环戊基的吡咯并嘧啶化合物 Download PDF

Info

Publication number
CN109311893A
CN109311893A CN201780037341.8A CN201780037341A CN109311893A CN 109311893 A CN109311893 A CN 109311893A CN 201780037341 A CN201780037341 A CN 201780037341A CN 109311893 A CN109311893 A CN 109311893A
Authority
CN
China
Prior art keywords
compound
acid
pyrrolo
pyrimidine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780037341.8A
Other languages
English (en)
Other versions
CN109311893B (zh
Inventor
祝力
刘洋健
张传玉
王鹤
罗鸿
孙颖慧
韩永信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN109311893A publication Critical patent/CN109311893A/zh
Application granted granted Critical
Publication of CN109311893B publication Critical patent/CN109311893B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种含有取代环戊基的吡咯并嘧啶化合物，具体涉及式A所示的化合物、其立体异构体、或其药学上可接受的盐。还涉及制备如式A所示的含有取代环戊基的吡咯并嘧啶化合物的方法、药物组合物、以及该化合物在治疗两面神激酶介导的疾病中的用途。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201780037341.8A 2016-06-16 2017-06-15 含有取代环戊基的吡咯并嘧啶化合物 Active CN109311893B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016104279501 2016-06-16
CN201610427950.1A CN107513067A (zh) 2016-06-16 2016-06-16 含有取代环戊基的吡咯并嘧啶化合物
PCT/CN2017/088424 WO2017215628A1 (zh) 2016-06-16 2017-06-15 含有取代环戊基的吡咯并嘧啶化合物

Publications (2)

Publication Number Publication Date
CN109311893A true CN109311893A (zh) 2019-02-05
CN109311893B CN109311893B (zh) 2020-09-04

Family

ID=60664307

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610427950.1A Pending CN107513067A (zh) 2016-06-16 2016-06-16 含有取代环戊基的吡咯并嘧啶化合物
CN201780037341.8A Active CN109311893B (zh) 2016-06-16 2017-06-15 含有取代环戊基的吡咯并嘧啶化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610427950.1A Pending CN107513067A (zh) 2016-06-16 2016-06-16 含有取代环戊基的吡咯并嘧啶化合物

Country Status (3)

Country Link
US (1) US10617692B2 (zh)
CN (2) CN107513067A (zh)
WO (1) WO2017215628A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107513067A (zh) * 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
WO2020135401A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
WO2021180093A1 (zh) * 2020-03-09 2021-09-16 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途
CN114085224A (zh) * 2020-08-25 2022-02-25 北京普祺医药科技有限公司 一种吡咯并嘧啶化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448826A (zh) * 2005-12-13 2009-06-03 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡咯和吡咯并[2,3-b]嘧啶
CN101815717A (zh) * 2007-06-13 2010-08-25 因塞特公司 JANUS激酶抑制剂(R)-3-(4-(7H-吡咯并[2，3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的代谢产物
CN102596960A (zh) * 2009-10-09 2012-07-18 因西特公司 3-(4-(7H-吡咯并[2，3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
CN107513067A (zh) * 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102366A2 (hu) 1998-06-04 2001-11-28 Abbott Laboratories Sejttapadást gátló, gyulladáscsökkentő hatású vegyületek
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
MXPA02005675A (es) 1999-12-10 2002-09-02 Pfizer Prod Inc Compuestos de pirrolo(2,3-d)pirimidina.
JP2006518381A (ja) 2003-02-07 2006-08-10 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
SE0301372D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
CN105777754B (zh) 2014-12-16 2019-07-26 北京赛林泰医药技术有限公司 吡咯并嘧啶化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448826A (zh) * 2005-12-13 2009-06-03 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡咯和吡咯并[2,3-b]嘧啶
CN101815717A (zh) * 2007-06-13 2010-08-25 因塞特公司 JANUS激酶抑制剂(R)-3-(4-(7H-吡咯并[2，3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的代谢产物
CN102596960A (zh) * 2009-10-09 2012-07-18 因西特公司 3-(4-(7H-吡咯并[2，3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
CN107513067A (zh) * 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物

Also Published As

Publication number Publication date
US20190183899A1 (en) 2019-06-20
CN107513067A (zh) 2017-12-26
WO2017215628A1 (zh) 2017-12-21
US10617692B2 (en) 2020-04-14
CN109311893B (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
EP4129986A1 (en) Substituted pyridazine compound
CN107001378B (zh) 吡咯并嘧啶化合物
EP2885288B1 (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
CN101815717B (zh) JANUS激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的代谢产物
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
CN102827170A (zh) 治疗活性组合物和它们的使用方法
JP2017518276A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
CN109311893A (zh) 含有取代环戊基的吡咯并嘧啶化合物
CN102827073A (zh) 治疗活性组合物和它们的使用方法
KR20120102604A (ko) 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
JP6986032B2 (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
EP4083038A1 (en) Pyridazinyl thiazolecarboxamide compound
CN104093712B (zh) 作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物
US8969345B2 (en) Dibenzooxepin derivative
IL267829A (en) New Amino-Imidazopyridine History as Janus Kinase Inhibitors and Their Pharmacological Use
CN112979656A (zh) 一类靶向降解btk蛋白的化合物
EP2921489B1 (en) 2-pyridone compound
CN114555565B (zh) 含氮并环化合物、其制备方法及用途
CN109476638A (zh) 吡唑衍生物、其组合物及治疗用途
CN116514772A (zh) 作为masp-2抑制剂的化合物、药物组合物及其制备方法和用途
CN109280028B (zh) 喹啉类化合物及其在dpp-4酶抑制剂的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190530

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd.

Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee before: Shouyao holding (Beijing) Co.,Ltd.

Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.